ភាគហ៊ុនរបស់ Avadel ធ្លាក់ចុះ 21% បន្ទាប់ពីបង្ហាញសំណើថ្មីរបស់ FDA សម្រាប់ថ្នាំ narcolepsy ពិសោធន៍

Shares of Avadel Pharmaceuticals PLC
AVDL,
+ 133.64%
tumbled 21.6% in premarket trading on Thursday after the company said in a securities filing that the Food and Drug Administration requested additional information for its experimental narcolepsy drug. Avadel said it now expects to get a FDA decision on the drug, FT218, by June of next year. The company’s stock is down 58.1% this year, while the S&P 500
SPX,
+ 2.47%
បានធ្លាក់ចុះ 16.5% ។